| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Mar, 2026 | Mar, 2026 |
| Sales | 89,060 | 65,440 | 45,230 | 0 | 0 |
| Sales Growth | +36.09% | +44.68% | unch | unch | unch |
| Net Income | -53,410 | -40,460 | -29,460 | 0 | 0 |
| Net Income Growth | -32.01% | -37.34% | unch | unch | unch |
Ceribell Inc (CBLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CeriBell Inc. is a commercial-stage medical technology company. It focused on transforming the diagnosis and management of patients with serious neurological conditions. The company is an AI-powered, rapidly deployable point-of-care electroencephalography platform designed to address the unmet needs of patients in the acute care setting. CeriBell Inc. is based in Sunnyvale, Calif.
Fiscal Year End Date: 12/31